Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
YieldMax Magnificent 7 Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.33. Which is the better fit depends on your goals.

ALNYYMAG
Market Cap
$29.60B
Sector
HealthIncome / Options Overlay
52-Week High
$491.22$15.98
52-Week Low
$205.48$10.76
Enterprise Value
$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG trades at $11.29, down 2.59% today, with technical indicators showing a bullish overall signal despite mixed oscillators. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.07 to $0.40 per share. Recent news highlights YieldMax's distribution announcements and analysis of the fund's option income strategy performance.

The fund's structured option strategy provides high income potential but faces NAV stability challenges during earnings volatility. Key risks include concentrated exposure to Magnificent Seven stocks and option strategy complexity. Technical support sits at $11-12 levels while the bullish moving average trend suggests potential upside momentum.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.

Read more on YMAG